-
公开(公告)号：US4888182A
公开(公告)日：1989-12-19
申请号：US019056
申请日：1987-02-26
申请人： Charles Y. C. Pak
发明人： Charles Y. C. Pak
IPC分类号： A61K31/19
CPC分类号： A61K31/19 , Y10S514/891
摘要： Methods and compositions useful for the treatment and prophylaxis of calcium renal stones are disclosed. The methods involve administering potassium citrate compositions to persons afflicted with or susceptible to calcium renal stone formations. A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the results of a comparative clinical assay indicate the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.
摘要翻译： 公开了用于治疗和预防钙肾结石的方法和组合物。 所述方法涉及将柠檬酸钾组合物施用于患有钙敏感性肾结石形成的患者或易受影响的人。 典型的剂量方案包括每天以分剂量施用约30至120毫克柠檬酸钾。 这种治疗有效地溶解现有的钙结石并防止形成新的钙结石。 此外，比较临床检验的结果表明柠檬酸钾在治疗尿酸结石时优于柠檬酸钠。 柠檬酸钾治疗可以避免钙肾结石形成，这种并发症通常与柠檬酸钠或碳酸氢钠碱化治疗相关。
-
12.发明授权Ultradense and more soluble and bioavailable preparations of calcium citrate 失效柠檬酸柠檬酸钙的超级和更可溶性和生物可利用的制剂
公开(公告)号：US4814177A
公开(公告)日：1989-03-21
申请号：US896651
申请日：1986-08-13
CPC分类号： A61K31/19 , A23L33/16 , A61K9/0007 , Y10S514/891
摘要： A calcium citrate composition having a bulk density greater than about 1.1 g/cc. Citric acid and a calcium compound are mixed to produce a mixture having a calcium compound/citric acid molar ratio of about 1.5. A hydrated mixture percent is produced by agitatively adding water to the mixture, although when desired the calcium compound, citric acid and water mayBACKGROUND OF THE INVENTIONA portion of the development of the present invention was supported by Grant No. P01-AM 20543 from the United States Government, National Institutes of Health.
摘要翻译： 体积密度大于约1.1g / cc的柠檬酸钙组合物。 将柠檬酸和钙化合物混合以产生钙化合物/柠檬酸摩尔比为约1.5的混合物。 通过向混合物中搅拌加水来产生水合的混合物百分数，尽管如果需要，钙化合物，柠檬酸和水可以在一个步骤中混合。 将水合混合物混合以促进柠檬酸与钙化合物的反应，并形成主要由直径在约1/64英寸至约1/16英寸之间的颗粒组成的颗粒状物质。 然后将造粒物质干燥至约10重量％至约13重量％之间的水分含量，以产生堆积密度大于约1.1g / cc的柠檬酸钙组合物。 对于柠檬酸钙片剂，该柠檬酸钙组合物通过将一种或多种压片粘合剂接合而形成压片组合物。 然后将压片组合物通过多工位压片机进料以形成高密度柠檬酸钙片剂。 高密度柠檬酸钙片剂大于约15重量％的钙，钙/柠檬酸盐摩尔比为约1.5。 这种片剂特征性地具有大于约1.5g / cc的密度，并且为了美学或其它目的可以用包含物质如糖，聚乙烯吡咯烷酮，碳酸钙和二氧化钛的混合物包衣。
-
公开(公告)号：US10251909B2
公开(公告)日：2019-04-09
申请号：US11673497
申请日：2007-02-09
申请人： Charles Y. C. Pak
发明人： Charles Y. C. Pak
摘要： The present invention includes compositions and methods for using a single pharmaceutical preparation of KMgCit is a convenient surrogate or to support the DASH diet in lowering blood pressure among patients with essential hypertension. Support is provided by potassium, magnesium and alkali, which overcome the underlying physiological-biochemical disturbances of essential hypertension, such as salt sensitivity, insulin resistance, low urinary pH, low serum magnesium and renal leak of calcium. Positive effects of KMgCitrate disclosed in normal subjects and patients with stones, provides assurance that KMgCitrate should ameliorate the above physiological-biochemical disturbances and associated disorders in patients with essential hypertension.
-
14.发明授权
公开(公告)号：US5228445A
公开(公告)日：1993-07-20
申请号：US813383
申请日：1991-12-26
申请人： Charles Y. C. Pak , Peter Antich
发明人： Charles Y. C. Pak , Peter Antich
IPC分类号： A61B8/08
CPC分类号： A61B8/0875 , G01N2291/0258 , G01N2291/02827 , G01N2291/102 , G01N2291/269
摘要： The invention involves a treatment process for improving the intrinsic quality of bone in osteoporotic patients. This can reduce the frequency of spinal fractures by inducing formation of bone which is mechanically stronger than that which it replaces. The process preferably comprises: administering an enteral form of sodium fluoride to maintain an individual's serum fluoride level from about 100 to about 200 ng/ml with a circadian fluctuation of less than about 75 ng/ml, and dietarily supplementing said individual with absorbable calcium (preferably calcium citrate). In one embodiment, sodium fluoride administration is interrupted temporarily (for about 30 to about 60 days in a 13 or 14 month cycle) to prevent loss of fluoride effectiveness and avert impaired mineralization of bone. Calcium is preferably maintained by an enteral dose of about 400 mg calcium twice daily. A vitamin D preparation may also be administered to the individual to further enhance bone strengthening. As a method for assessing response, periodic noninvasive in vivo measurements of intrinsic bone quality are made by reflection ultrasound, and the treatment regimen is maintained, altered or discontinued based on clinical assessment of the results. In this way, clinical response to the treatment is evaluated to guide its continued application.
摘要翻译： 本发明涉及用于改善骨质疏松患者骨质量的治疗方法。 这可以通过诱导骨的形成来降低脊柱骨折的频率，该骨比机械地强于骨代替骨。 该方法优选包括：施用肠内形式的氟化钠以维持个体的血清氟化物水平为约100至约200ng / ml，昼夜波动小于约75ng / ml，并且用所述个体用可吸收的钙进行膳食补充（ 优选柠檬酸钙）。 在一个实施方案中，氟化钠施用暂时中断（在13或14个月周期中约30至约60天），以防止氟化物失效的丧失，并避免骨质矿化。 钙优选通过约400mg钙的肠内剂量每天维持两次。 还可以向个体施用维生素D制剂以进一步增强骨骼的强化。 作为评估反应的方法，通过反射超声进行固有骨质量的周期性非侵入性体内测量，并且基于结果的临床评估来维持，改变或停止治疗方案。 以这种方式，对治疗的临床反应进行评估以指导其继续应用。
-
公开(公告)号：US5219889A
公开(公告)日：1993-06-15
申请号：US803689
申请日：1991-12-03
IPC分类号： A23L1/304 , A61K31/19 , C07C59/265
CPC分类号： A61K31/19 , A23L33/16 , C07C59/265
摘要： A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.
摘要翻译： 公开了一种补充膳食钾，镁和柠檬酸盐的方法，其包括在单一盐中口服施用有效量的柠檬酸钾钾。 还公开了通过在单一盐中施用柠檬酸钾钾来降低尿钙和草酸盐的方法。
-
公开(公告)号：US4772467A
公开(公告)日：1988-09-20
申请号：US807530
申请日：1985-12-11
申请人： Charles Y. C. Pak
发明人： Charles Y. C. Pak
CPC分类号： A61K31/19 , Y10S514/891
摘要： A process for dietary calcium supplementation. Oral dosage of a composition comprising calcium citrate is utilized to provide an efficiently absorbable chemical form of calcium, while raising urinary level of citrate. Because of improved absorption of calcium, osteoporosis development is precluded. Since citrate retards precipitation of stone-forming calcium stones, the risk of calcium nephrolithiasis (resulting from calcium supplementation) is reduced.
摘要翻译： 膳食钙补充的过程。 使用包含柠檬酸钙的组合物的口服剂量来提供有效吸收的化学形式的钙，同时提高柠檬酸盐的尿液水平。 由于钙的吸收改善，骨质疏松症的发展被排除。 由于柠檬酸盐阻滞石块形成钙结石的沉淀，因此减少了由钙补充引起的钙肾结石病的风险。
-
17.发明授权Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis 有权柠檬酸钾粉末混合用于治疗肾结石和骨质疏松症公开(公告)号：US08216614B2
公开(公告)日：2012-07-10
申请号：US12784305
申请日：2010-05-20
CPC分类号： A61K33/08 , A61K31/19 , A61K33/10 , A61K2300/00
摘要： A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.
摘要翻译： 公开了一种组合物，其包含柠檬酸钾和柠檬酸钙作为纯化学盐的混合物的粉末混合物，以及制备和使用该组合物的方法。 该组合物可用于治疗和预防肾结石和骨质疏松症，并且比常用的钾和钙补充剂更好地输送钾和钙。
-
公开(公告)号：US06287607B1
公开(公告)日：2001-09-11
申请号：US09356649
申请日：1999-07-19
IPC分类号： A61K3306
摘要： A composition useful as a dietary supplement for providing potassium, calcium, and citrate is presented, as well as processes for producing the composition, and methods for using the composition as a dietary supplement. Administration of the composition counters bone loss associated with aging or menopause by providing bioavailable calcium and, simultaneously, delivering alkali load. In addition, administration of the composition produces a substantial increase in urinary citrate, which counters kidney-stone formation.
-
19.发明授权Liquid calcium supplementation from readily soluble mixtures of calcium compound and citric acid 失效从钙化合物和柠檬酸的易溶混合物中补充液体钙
公开(公告)号：US4851221A
公开(公告)日：1989-07-25
申请号：US935666
申请日：1986-11-26
IPC分类号： A23L2/52 , A23L1/304 , A23L2/38 , A23L2/68 , A61K31/00 , A61K31/19 , A61K33/06 , A61P3/00 , A61P3/02 , A61P3/14 , A61P43/00
摘要： The present invention comprises a composition of matter consisting essentially of citric acid and one or more calcium compounds selected from the group consisting of calcium hydroxide, calcium carbonate and calcium oxide. The composition of matter is preferably a substantially dry mixture which may be used, for example, as a powder for making an "instant" beverage of potable liquid. A preferred calcium compound/citric acid molar ratio in the composition of matter of the present invention is between about 0.6 and about 1.5.In a most preferred embodiment, the composition of matter of the present invention consists essentially of calcium hydroxide and citric acid having a calcium compound/citric acid or calcium hydroxide/citric acid molar ratio of about 1.25.The composition of matter of the present invention has a utility demostrated by dissolution in water to form a liquid dietary calcium supplement comprising soluble calcium citrate. This composition of matter may comprise one or more of a flavorant, lubricant, sweetener or colorant usable to maintain a powdery texture or to enhance the flavor of a beverage prepared therefrom.
摘要翻译： 本发明包括基本上由柠檬酸和一种或多种选自氢氧化钙，碳酸钙和氧化钙的钙化合物组成的物质组合物。 物质的组成优选为基本上干燥的混合物，其可以用作例如用于制造饮用液体的“即时”饮料的粉末。 本发明物质组合物中优选的钙化合物/柠檬酸摩尔比为约0.6至约1.5。 在最优选的实施方案中，本发明的物质组成基本上由具有约1.25的钙化合物/柠檬酸或氢氧化钙/柠檬酸摩尔比的氢氧化钙和柠檬酸组成。 本发明的物质组成具有通过在水中溶解形成含有可溶性柠檬酸钙的液体膳食钙补充剂的功效。 该物质组合物可以包含一种或多种调味剂，润滑剂，甜味剂或着色剂，其可用于保持粉末质地或增强由其制备的饮料的风味。
-
20.发明授权Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis 失效缓释氟化钠片，制法及治疗骨质疏松症的方法
公开(公告)号：US4726952A
公开(公告)日：1988-02-23
申请号：US842304
申请日：1986-03-21
CPC分类号： A61K9/2013 , A61K33/16
摘要： A novel use for a slow-release sodium fluoride preparation. Such slow-release sodium preparation is shown to provide a safe but effective level of fluoride in serum, optimal for the treatment of osteoporosis. It minimizes gastrointestinal side effects by limiting the amount of fluoride released in the stomach and it reduces rheumatic complications by avoiding toxic levels of fluoride in serum. The amount of fluoride absorbed is nevertheless sufficient to stimulate bone formation and prevent fractures. Thus, the maintenance of serum fluoride as encompassed in this invention, allows for a safe and effective treatment of osteoporosis.
摘要翻译： 缓释氟化钠制剂的新用途。 这种缓释钠制剂显示提供了血清中安全但有效的氟化物水平，是治疗骨质疏松症最佳的。 它通过限制胃中释放的氟化物的量来最大限度地减少胃肠道副作用，并通过避免血清中的氟化物含量降低风湿并发症。 然而，吸收的氟化物的量足以刺激骨形成并防止骨折。 因此，维持本发明所包含的血清氟化物，可以安全有效地治疗骨质疏松症。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.034 秒)
